Skip to main content

Table 1 Clinical, biological, US and PET data

From: 18F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab

Patient

Clinical response W16

Clinical response W24

Number of PET+ joints

cSUV

Composite SUV index

Number of US+ joints

Cumulative synovial thickness (mm)

CRP (mg/l)

DAS28

   

J0

W16

J0

W16

J0

W16

J0

W16

J0

W16

J0

W16

J0

W16

W24

1

R

T

8

8

8.8

12.1

2.9

4

4

10

8

21.3

2.8

5.2

5,1

3.2

6.3

2

R

S

21

10

26.9

6.6

23.5

2.8

23

6

62.3

8.6

10.3

0.9

7

3.4

4.9

3

R

T

6

7

10.3

16.1

2.6

4.7

13

7

39.3

40

4.3

27.5

5.5

4.3

6.5

4

R

S

9

6

21.1

13.7

7.9

3.4

7

5

21.6

19

34.9

29.7

7

4.7

3.7

5

N-R

N-R

8

9

15.8

13.2

5.3

5

8

4

13.8

9.6

4.5

1.3

6.5

6.9

6.9

6

N-R

N-R

18

24

24.3

46.5

18.2

46.5

8

21

17.1

50.6

13.9

84.6

7.1

8.1

8.2

7

R

T

13

17

26.4

38.3

14.3

27.1

14

16

48.6

49.3

58.1

40.4

8.6

6.4

8.8

8

N-R

N-R

5

3

7.4

3.9

1.5

0.5

4

8

7.1

13.5

22

10

5.1

4.2

4.3

9

R

T

8

11

7.5

11.4

2.5

5.2

11

3

22.9

6.3

1

3.6

7.1

3.5

6.2

10

R

T

23

23

46.3

30.8

44.4

29.5

26

12

104.8

30.4

41.4

9.6

8.1

4.7

7.9

11

R

S

5

6

11.8

14.4

2.5

3.6

7

6

24

19.7

14.3

11.7

6.8

4.1

5.3

12

R

T

9

14

18.3

18.3

6.9

10.7

12

17

30.5

38.8

32.3

17.1

5.9

3.2

4.7

13

N-R

N-R

4

4

8.2

8.2

1.4

1.4

4

8

16.1

19.2

0.9

2.4

6.4

6.2

6.4

14

N-R

N-R

0

2

0

3.7

0

0.3

7

5

13.5

9.9

1.3

2.1

6.3

5.3

5.2

15

R

S

0

0

0

0

0

0

4

3

12

4.5

3

1.8

4.8

3.5

3.5

  1. R responder, N-R non-responder, T transient, S sustained, J0 baseline, W16 week 16